OIG Gets Mixed Results On Question Of Medicaid Pharmacy Reimbursement
The latest analysis of Medicaid's reimbursement for multiple-source drugs finds that with an average manufacturer price-based federal upper limit, pharmacies could be reimbursed more than they paid for the drugs overall, even as a number of drugs are under-reimbursed. But retail pharmacies see the report and others like it as missing the bigger picture
You may also be interested in...
Despite favoring provisions in the Senate version of the health care reform bill that pertain to Medicaid's pharmacy reimbursement for generic drugs, the National Community Pharmacists Association is continuing to fight for a better deal
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials